- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Roxane Labs' generic prostate drug gets tentative approval from FDA
FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved the latest drug in BD's Simplist line, the company said Thursday.
BD announced the approval of ondansetron injection in the 4 mg/2 mL strength, an injectable drug used to prevent nausea and vomiting after surgery. The drug is currently on the FDA's drug shortage list due to recent increases in demand and supply issues faced by other manufactures, BD said.
"We're proud to be expanding our BD Simplist products with a drug like ondansetron injection, USP, which is in high demand among clinicians and fills a need for an intervention that can be administered quickly," BD Rx president Mark Sebree said. "As we establish our product line with a third drug approval, we are seeing even further indication of the positive responses to our new BD Simplist prefilled injectables, especially among repeat customers."
BD announced its plan to manufacture generic drugs through its BD Rx division, and its BD Simplist product line currently contains two other products.